Ropes & Gray represented Viridian Therapeutics in an exclusive licensing and collaboration deal with Kissei Pharmaceutical to develop and market thyroid eye disease therapy veligrotug and VRDN-003 in Japan. The transaction was announced on July 30.
Under the agreement, Viridian will receive a $70 million upfront payment with potential to receive an additional $315 million in milestone payments as well as tiered royalties on net sales in Japan.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associates Nicole Rohr and Ryan Kramer and included tax partner David Saltzman.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
